Follow
Michelle S. Brauer
Michelle S. Brauer
Associate Research Scientist, Precision Health Economics
Verified email at precisionhealtheconomics.com
Title
Cited by
Cited by
Year
Lifetime economic burden of Crohn’s disease and ulcerative colitis by age at diagnosis
GR Lichtenstein, A Shahabi, SA Seabury, DN Lakdawalla, OD Espinosa, ...
Clinical Gastroenterology and Hepatology 18 (4), 889-897. e10, 2020
782020
Long-term health and economic value of improved mobility among older adults in the United States
M Kabiri, M Brauer, J Shafrin, J Sullivan, TM Gill, DP Goldman
Value in Health 21 (7), 792-798, 2018
292018
An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: does …
J Shafrin, M Skornicki, M Brauer, J Villeneuve, M Lees, N Hertel, ...
Health Policy 122 (6), 607-613, 2018
242018
The potential impact of CAR T-cell treatment delays on society
JT Snider, M Brauer, R Kee, K Batt, P Karaca-Mandic, J Zhang, ...
Am J Manag Care 25 (8), 379-386, 2019
152019
Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illness
J Shafrin, K Bognar, K Everson, M Brauer, DN Lakdawalla, FM Forma
ClinicoEconomics and outcomes research, 573-585, 2018
142018
Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis
E van Eijndhoven, M Brauer, R Kee, J MacEwan, L Mucha, SL Wong, ...
Journal of Medical Economics 23 (5), 474-483, 2020
102020
CAR-T therapy and historical trends in effectiveness and cost–effectiveness of oncology treatments
JR Baumgardner, MS Brauer, J Zhang, Y Hao, Z Liu, DN Lakdawalla
Journal of Comparative Effectiveness Research 9 (5), 327-340, 2020
102020
Increased lifetime risk of intestinal complications and extraintestinal manifestations in Crohn’s disease and ulcerative colitis
GR Lichtenstein, A Shahabi, SA Seabury, DN Lakdawalla, OD Espinosa, ...
Gastroenterology & Hepatology 18 (1), 32, 2022
92022
The economic value of CTL019 therapy for pediatric patients with relapsed and refractory acute lymphoblastic leukemia in the United Kingdom
J Snider, M Brauer, Y Hao, P Karaca-Mandic, MG Tebeka, J Zhang, K Batt
Blood 130, 1330, 2017
72017
Expanding cost-effectiveness analysis to all of health care: comparisons between CEAs on pharmaceuticals and medical/surgical procedures
J Baumgardner, M Brauer, M Skornicki, P Neumann
Los Angeles, 2018
52018
Complications of Crohn's Disease and Ulcerative Colitis: Understanding the Lifetime Risks: 716
GR Lichtenstein, A Shahabi, SA Seabury, D Lakdawalla, OD Espinosa, ...
Official journal of the American College of Gastroenterology| ACG 112, S395-S396, 2017
52017
The Economic Burden of Crohn's Disease and Ulcerative Colitis in the United States: A Lifetime Healthcare Cost Analysis: 2017 Presidential Poster Award: 715
GR Lichtenstein, A Shahabi, SA Seabury, D Lakdawalla, OD Espinosa, ...
Official journal of the American College of Gastroenterology| ACG 112, S395-S396, 2017
32017
The social value of tisagenlecleucel, a CAR-T cell therapy, for the treatment of relapsed or refractory pediatric acute lymphoblastic leukemia in the United States: What are …
JT Snider, M Brauer, K Batt, P Karaca-Mandic, J Zhang, DP Goldman
Journal of Clinical Oncology 36 (15_suppl), 10529-10529, 2018
22018
P014 AVERAGE ANNUAL HEALTHCARE COSTS FOR PEDIATRIC AND ADULT PATIENTS WITH CROHN’S DISEASE OR ULCERATIVE COLITIS
RN Baldassano, A Shahabi, SA Seabury, D Lakdawalla, O Diaz, S Green, ...
Inflammatory Bowel Diseases 24 (suppl_1), S6-S6, 2018
22018
Alternative payment models and innovation: a case study of US health system adoption of a sacubitril/valsartan to treat acute decompensated heart failure
J Shafrin, ER Aliyev, M Brauer, S Park, X Shen
Journal of Medical Economics 23 (12), 1450-1460, 2020
12020
Adoption of Sacubitril/Valsartan to Treat Acute Decompensated Heart Failure Improves Health System Finances Under Value-based Alternative Payment Models
J Shafrin, ER Aliyev, M Brauer, S Park, X Shen
Circulation 142 (Suppl_3), A14302-A14302, 2020
12020
CAR-T therapy displays favorable gains in health outcomes and competitive cost-effectiveness when compared with past innovative cancer treatments
J Baumgardner, K Everson, M Brauer, J Zhang, Y Hao, J Liu, ...
Blood 132, 322, 2018
12018
The potential value of rapid, cloud-enabled onsite testing for the diagnosis of rheumatoid arthritis in the United States
K Bognar, J Shafrin, M Brauer, L Zhao, R Hockett, M O’Neil, A Jena
Journal of Medical Economics 21 (11), 1057-1066, 2018
2018
Does knowledge of patient non-compliance change prescribing behavior in the real world? a claims-based analysis of patients with serious mental illness
K Bognar, K Everson, M Brauer, FM Forma
2018
Do multiple sclerosis cost-effectiveness studies follow best practice guidelines? A review of 5 case studies (P3. 399)
J Shafrin, D Kantor, M Brauer, J Ko, V Herrera, D Goldman
Neurology 88 (16 Supplement), 2017
2017
The system can't perform the operation now. Try again later.
Articles 1–20